Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. - Wikidata - wikimedia - TriplyDB

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.

http://www.wikidata.org/entity/Q39129373

about

Site-specific functionalization of proteins and their applications to therapeutic antibodies Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Advances in Antibody Design CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.Design and applications of bispecific heterodimers: molecular imaging and beyond Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing β-Glucan and MP65 Determinants in Candida Species.Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry.Improving target cell specificity using a novel monovalent bispecific IgG design Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Computationally Designed Bispecific Antibodies using Negative State Repertoires.Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Recent developments in antibody-based assays for the detection of bacterial toxins.The maturation of antibody technology for the HIV epidemic.Promise and challenges on the horizon of MET-targeted cancer therapeutics Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.miR-143 targets MAPK7 in CHO cells and induces a hyperproductive phenotype to enhance production of difficult-to-express proteins.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.Increased Potency of a Bi-specific TL1A-ADAM17 (TACE) Inhibitor by Cell Surface Targeting.A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1.An efficient route to bispecific antibody production using single-reactor mammalian co-culture.Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry.

P2860

Q26830699-D2AFF677-B090-4CF1-AC42-37847783ED0E Q27679191-0036A964-4CDF-4626-BB5C-9A447D95F24D Q28072319-C572840A-5BD4-4650-BE0F-F2FD4B560C54 Q28817608-021F0395-9147-4B4C-88C0-723D81A21B31 Q30360904-A6B2E4AC-3397-41B9-9AD5-8A969B51072A Q33732587-2507854E-FD7E-44E3-B576-0CEDC8668E86 Q34548319-9FC70622-C3F9-4E20-8358-367C54EAFDB1 Q34550963-E244B61B-5F50-4AF2-BDE9-A6D734375616 Q34601167-0E8C9002-5C6D-4D82-86E4-E0D860BC89F4 Q35119802-8E79C7D8-686C-4E0A-A17F-7490905DE0F6 Q35199371-7D109713-029C-4BA3-AED9-A5BCC95C0B1D Q35859635-E628DE33-AA10-4CD9-85E7-272742A1B490 Q35918232-0CE11769-E0CD-4BCE-BEBC-69E545B31BFE Q35947503-10AB288B-8EEC-416F-A3C1-E64AF66E9983 Q36179288-B01C1178-675A-400E-8A30-4A6CAA552DE1 Q36213090-97BA65E7-4472-4DF3-89EA-D9EA045F25D8 Q36216009-E1B54E7B-FA43-43F5-A77A-F48B6699CF13 Q36363779-369E9BF2-8167-472C-9627-C8AB02CAA8D9 Q36899812-090899BB-36BC-4A03-8785-85C8FA8ACA4C Q37168393-15E7686E-B7FA-4678-8714-AB1CA68FAD75 Q37396968-9BDDD5C9-D17A-4C9A-97CA-FAE4648A4137 Q37496563-AA35E515-4427-4700-9E6C-DB650BEDB5AB Q37631316-C9299BA6-ACB2-4032-900D-726A14CCCCDB Q38204596-AB22626F-EED9-4AE3-9584-6AAB90EC9EC8 Q38209477-237FB943-B383-47CC-AEB8-FD29DCA83C93 Q38502350-1C920C97-35AC-4623-9858-F032498B4DF7 Q38706016-A76A46F5-F3B5-4ED9-8D7A-08EE3F553639 Q38748906-1E82284F-1D72-43EA-BA4B-6783A363FFAA Q38858726-8BDE140E-278E-4839-9A5A-31A9A9D6CDE1 Q38861238-08477D39-F692-4158-8E1B-E755D7C64F8E Q39062177-E0916374-E091-4CB9-A770-7513A5E515E2 Q40407506-C51C31AE-FEEF-4C03-BFB2-4CBC44071C80 Q40612349-24783720-5CFB-4225-ABD6-24475624A3D4 Q41489391-DC741EB3-8F60-463B-B095-1677D2BF2CAC Q41525669-8F9F50C7-201A-4698-B83F-99C5BEAD1785 Q41603684-5F3C4350-A055-401E-90F0-30582ED61159 Q41675418-72317C49-0AFB-4BC1-BF0C-867750724378 Q41719908-998FC2A8-62DD-4F3D-AD45-6E10409651FD Q41838529-11AD02C7-06D8-4112-8EF9-F1A77459FAAA Q41899683-0954E9F6-8909-4A20-B189-76BCD87CB3EF

P2860

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.

http://www.wikidata.org/entity/Q39129373

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bispecific antibodies with nat ...... two distinct half-antibodies.

@en

Bispecific antibodies with nat ...... two distinct half-antibodies.

@nl

type

label

Bispecific antibodies with nat ...... two distinct half-antibodies.

@en

Bispecific antibodies with nat ...... two distinct half-antibodies.

@nl

prefLabel

Bispecific antibodies with nat ...... two distinct half-antibodies.

@en

Bispecific antibodies with nat ...... two distinct half-antibodies.

@nl

P1433

Q39129373-AAFFABD7-9C1D-4B3E-9BFD-5D8104E2B269

P1476

Q39129373-4807ADA5-597B-45B2-A8C1-AEEDB80A6E55

P2093

Q39129373-20F82960-D375-4DE2-9A30-A5D177836940

Q39129373-2A6CB681-970C-41F1-A639-81AE68A8D8B6

Q39129373-4E84983E-03BC-4895-BF9E-6C0AB3F2B4BB

Q39129373-68D2B98E-9283-438A-A007-26C7A39AF570

Q39129373-8744E7C4-AEA3-49C8-A023-C73CC57C8BB0

Q39129373-953B00CD-79C3-4AE0-95B2-2C5DBACEC15F

Q39129373-9AED2553-AC6A-48D1-ADE4-6161FF799D2C

Q39129373-B42F5F59-F81D-4E2E-AA31-4D7C997FCAD8

Q39129373-C562958A-6907-40BA-807B-E94E56056C58

Q39129373-F92B487D-D3AF-42EA-86ED-77DBB67AB27A

P2860

Q39129373-0D85A25D-D988-4C95-9560-B6A9F32C4E74

Q39129373-1393BBA7-BFE9-4775-A4A1-E945A93C52CC

Q39129373-18CAD1A1-921C-4018-9302-54B51D6B8197

Q39129373-1CEB79BC-8EC4-4767-9785-848942273E53

Q39129373-2169453E-4DB2-41AE-A631-79A80F6813A2

Q39129373-3A8C83FD-8991-4161-BF15-0E132E2140F2

Q39129373-40789657-DA9D-41A5-8713-760DDC357370

Q39129373-51335390-1728-42C3-BA57-700A7DFD44E9

Q39129373-5EAB123C-4566-482B-B662-E4E053685123

Q39129373-684936C6-0BD7-4912-8132-41237D554898

P2888

Q39129373-195509FF-BC36-419C-8138-4DF15897DBAE

P304

Q39129373-989B3B3B-C7A0-4CA5-8D64-E26160F6F1FB

P31

Q39129373-6F24DAA3-DECC-40AD-A02B-87A07818C3FE

P356

Q39129373-DD6FB997-B050-4849-962E-7D5C68822C59

P433

Q39129373-0BBF6E57-5A21-4007-B305-6D7AB46363EB

P478

Q39129373-149EB791-3226-4E78-B2AA-D4E953FD03C4

P577

Q39129373-4BBBFFE7-DA43-4C0C-AAC7-D3F12C531581

P5875

Q39129373-69AAEF9D-1E5B-4C7F-9D76-18000ECA3AC3

P6179

Q39129373-1E2357B9-F32A-4619-85A4-559A45FEB714

P698

Q39129373-D2B87743-4B8C-457F-A9C8-21C8D68A1E76

P921

Q39129373-53C2ED6E-D315-4B15-A0CB-8232F7142CF1

P356

P1433

Nature Biotechnology

P1476

Bispecific antibodies with nat ...... two distinct half-antibodies.

@en

P2093

Arthur Huang

http://www.w3.org/2001/XMLSchema#string

Christoph Spiess

http://www.w3.org/2001/XMLSchema#string

Daniel G Yansura

http://www.w3.org/2001/XMLSchema#string

Diego Ellerman

http://www.w3.org/2001/XMLSchema#string

Dorothea Reilly

http://www.w3.org/2001/XMLSchema#string

Jing Peng

http://www.w3.org/2001/XMLSchema#string

Justin M Scheer

http://www.w3.org/2001/XMLSchema#string

Mark Merchant

http://www.w3.org/2001/XMLSchema#string

Nai-Ying Yang

http://www.w3.org/2001/XMLSchema#string

Whitney Shatz

http://www.w3.org/2001/XMLSchema#string

P2860

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

An efficient route to human bispecific IgG.

Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli.

Optimized expression of full-length IgG1 antibody in a common E. coli strain.

P2888

P304

753-758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.2621

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247156745

http://www.w3.org/2001/XMLSchema#string

P6179

1017245992

http://www.w3.org/2001/XMLSchema#string

P698

23831709

http://www.w3.org/2001/XMLSchema#string

P921